Market Overview

Bernstein Says Generic Copaxone Win Could Help Momenta Break through $20 Level

Related MNTA
Momenta Pharmaceuticals Spikes Up Following FDA News On Copaxone
Benzinga's M&A Chatter for Tuesday March 31, 2015
Prothena (PRTA) Posts Narrower-than-Expected Loss in Q1 - Analyst Blog (Zacks)
Related TEVA
Report Sees 'Cognitive Dissonance' In Mylan's Internal Price Target
Analyst: Mylan Shareholders Might Get Convinced By Vigodman Letter
Leading Stock Mallinckrodt Delivers Strong Results As Base Forms (Investor's Business Daily)

Momenta Pharmaceuticals (NASDAQ: MNTA) shares spiked sharply Friday following news of a legal ruling invalidating Teva Pharmaceutical's (NYSE: TEVA) patents on Copaxone in 2015 and partly invalidating its 2014 patents.

Bernstein analyst Ronny Gal sees a 75 percent chance of the court decision being favorable for Momenta. The ruling could open the door to Momenta introducing a generic Copaxone within the next few months, according to Gal.

If Momenta is able to introduce the first generic Copaxone by May 2014, Gal believes shares could be valued at $30. This is nearly twice the $15.35 level shares were trading at prior to Friday's spike.

Gal believes a later release by Q4 2015 could spell upside of 30 percent from current levels to $23 per share.

Gal rates Momenta at Outperform with a $20 price target.

Latest Ratings for MNTA

May 2015Leerink SwannMaintainsOutperform
Jan 2015Maxim GroupDowngradesBuySell
Jun 2014Goldman SachsInitiates Coverage onBuy

View More Analyst Ratings for MNTA
View the Latest Analyst Ratings

Posted-In: Analyst Color News FDA Legal Analyst Ratings Movers


Related Articles (MNTA + TEVA)

Around the Web, We're Loving...

Get Benzinga's Newsletters